GLP-1 Analogues Market Size & Growth Forecast to 2033

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033

USD 170.75 BN

MARKET SIZE, 2033

CAGR 13%

(2025-2033)

350

REPORT PAGES

450

MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. Factors such as increasing manufacturing capacities and capabilities are enhancing supply capacity to meet surging global demand for these therapies. Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption. Moreover, the rising prevalence of obesity and type 2 diabetes (T2D) globally continues to significantly boost market demand, as GLP-1 agonists play an essential role in the treatment and management of these conditions.

KEY TAKEAWAYS

BY PRODUCT

Ozempic dominated the GLP-1 agonists market owing to its high adoption for the management of type 2 diabetes, wide geographic availability, and a strong brand recognition.
BY FORMAT

The GLP-1 agonists market is segmented by format into single-dose, multi-dose, and tablet forms. The single-dose segment held the largest share, owing primarily to its ease of administration and convenience for patients.
BY INDICATION

The diabetes indication segment accounted for the largest share of the market. These drugs effectively lower blood glucose levels and provide cardiovascular and renal benefits, making them a preferred treatment option in diabetes care.
BY REGION

The GLP-1 agonists market covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America contributes the largest share to the market as the region has a structured ecosystem for adopting GLP-1 analogs. Investments are significant in the region, driving rapid product launches, clinical trials for new indications, and early adoption of innovative GLP-1 formulations, including oral and long-acting injectables.
COMPETITIVE LANDSCAPE

Major market players have adopted organic and inorganic strategies, including partnerships and investments. For instance, in September 2025, Pfizer announced plans to acquire Metsera, entering into a definitive agreement. This acquisition is aimed at enhancing its portfolio with the addition of Metsera's Next-Generation Obesity Portfolio.

The GLP-1 agonists market is projected to experience strong growth during the forecast period, propelled by ongoing advances in drug delivery technologies and the increasing adoption of GLP-1 therapies for diabetes and obesity management. Rising demand for effective weight reduction strategies and improved glycemic control, especially in regions facing surging rates of metabolic disorders, is a key factor driving market expansion. The market's growth is further supported by the approval of new indications, innovative product launches such as oral GLP-1 formulations, and wider integration of these drugs into home care and fitness settings.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

Semaglutide and Tirzepatide have been a source of disruption in the overall healthcare market. While the impact of GLP-1 on health outcomes for diabetes and obesity has been revolutionary, payors are actively looking to mitigate projected health costs. Novel providers such as gyms/ weight management centers have emerged by incorporating GLP-1 medications. In the coming years, patients and providers will have the options of newly launched biosimilars, novel GLP-1s, combination drugs, and approvals for allied indications. These disruptions are expected to drive growth and immense changes in the GLP-1 agonists market.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Expanding manufacturing capacity
Shift of GLP-1 drugs from diabetes specialty to broader treatment option

RESTRAINTS

Impact
Level

Stringent cost and payer controls

OPPORTUNITIES

Impact
Level

Increasing studies on oral GLP-1

CHALLENGES

Impact
Level

Counterfeits and compounded GLP-1 gray market
Safety, tolerability, and persistence issues

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Expanding manufacturing capacity

Rapid expansion of manufacturing capacity is driving growth across the pharmaceutical market, especially for high-demand drugs like GLP-1 analogs. New facilities and technological upgrades enable companies to scale production, meet global supply needs, and respond quickly to surging patient demand. Investments in advanced manufacturing allow for improved efficiency, cost savings, and higher product quality. Key players focus on constructing dedicated sites for active pharmaceutical ingredients (APIs) and finished dosage forms, enhancing their ability to launch new therapies and support pipeline commercialization.

Restraint: Stringent cost and payer controls

Stringent cost and payer controls are a significant restraint in the GLP-1 drugs market due to the high prices associated with these therapies. Payers and insurers are increasingly implementing restrictive coverage policies, such as limiting patient eligibility criteria, reducing prescription durations from 90 to 30 days, and favoring single-drug formularies to contain escalating costs. The rapid rise in demand for GLP-1 drugs has led to substantial increases in pharmacy spend and insurance premiums, causing financial strain on public and private payers.

Opportunity: Increasing studies on oral GLP-1

The momentum for oral GLP-1 therapies presents a significant opportunity for market expansion. Oral formulations overcome barriers associated with injectable drugs, offering greater convenience and acceptance among patients who are reluctant or unable to use injections. This innovation is likely to boost adherence, increase prescription rates, and tap into new patient segments in both diabetes and obesity management. Pharmaceutical companies are intensifying R&D investments to optimize oral GLP-1 efficacy and expand indication approvals. As these products launch and gain regulatory endorsements, they are expected to drive substantial growth and diversify therapeutic options in the metabolic disease market. Rybelsus, the only oral GLP-1, is expected to be joined by Orforglipron by 2027-28.

Challenge: Counterfeits and compounded GLP-1 gray market

The market faces growing challenges from counterfeit and compounded GLP-1 products, leading to safety risks and regulatory concerns. The proliferation of unauthorized manufacturers and online sellers can cause confusion among consumers, fuel market noise, and undermine trust in legitimate therapies. Counterfeit drugs often lack efficacy, pose health hazards, and erode brand reputation for innovator companies. Effective education, tighter controls, and coordinated global action are essential to protect patient safety and maintain market integrity.

GLP-1 Agonists Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Equinox fitness clubs have incorporated new programs for clients on GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro.	Targeted conditioning leading to less muscle loss and more fat loss \| Lesser side effects
	Nestle Health Science has developed and launched a GLP-1 Nutrition support platform for use in the US.	Preserving lean muscle mass \| Supports an adequate daily consumption of micronutrients

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The GLP-1 agonists ecosystem encompasses a network of interdependent stakeholders, including drug manufacturers, contract research and manufacturing organizations, healthcare providers, and end users. This landscape features major pharmaceutical companies developing GLP-1 therapies, service providers supporting clinical trials, regulatory agencies overseeing safety and efficacy, and end users such as hospitals, clinics, and home care settings. These diverse parties collaborate and innovate to advance therapeutic offerings, enhance patient outcomes, and drive the growth and evolution of the GLP-1 agonists market.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

GLP-1 Agonists Market, By Product

The Ozempic (semaglutide) segment accounted for the largest market revenue share in 2024. The large share of this segment can be attributed to the growing adoption of Ozempic (semaglutide),

GLP-1 Agonists Market, By Indication

The diabetes segment dominated the overall GLP-1 agonists market in 2024. This is mainly due to the growing consumption of GLP-1 drugs for diabetes management and a strong pipeline further supporting growth.

GLP-1 Agonists Market, By End User

In 2024, the home care settings and fitness/weight management facilities accounted for the largest share in the global GLP-1 agonists market. This can be attributed to the growing adoption of GLP-1 drugs for weight management, increasing approvals for obesity indication, and the convenience of administering these drugs in home care settings.

REGION

North America to be the fastest-growing region in the global GLP-1 agonists market during the forecast period

The Asia Pacific GLP-1 agonists market is expected to register the highest CAGR during the forecast period. This is mainly driven by a high prevalence of type 2 diabetes and obesity in the region. The region has seen rapid adoption driven by growing healthcare infrastructure, and widening access to advanced healthcare has boosted demand for cutting-edge therapies. Increased government focus on metabolic disease management and strategic investment by global pharma companies are accelerating product launches and adoption across the region. Rising patient awareness and improving affordability also contribute to expanding GLP-1 drug uptake.

GLP-1 Agonists Market: COMPANY EVALUATION MATRIX

In the GLP-1 agonists market matrix, Novo Nordisk (Star) stands out as the leading player, supported by a strong product portfolio and global market presence, driving widespread usage in diabetes and obesity management. Boehringer Ingelheim International GmbH (Emerging Leader) is classified as a rapidly emerging leader, with a focus on developing a novel GLP-1 agonist (Survodutide) in phase 3 of clinical development. While Novo Nordisk maintains dominance through scale and innovation, Boehringer Ingelheim is demonstrating significant growth potential.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size in 2024 (Value)	USD 53.74 Billion
Market Forecast in 2033 (Value)	USD 170.75 Billion
Growth Rate	CAGR of 13.0% from 2025–2033
Years Considered	2023–2033
Base Year	2024
Forecast Period	2025-2033
Units Considered	Value (USD Million), Volume
Report Coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered	By Product: Ozempic Wegovy Mounjaro Zepbound Rybelsus Trulicity Orforglipron Cagrisema Survodutide Retatrutide Semaglutide Biosimilars Other GLP-1 Biosimilars Other Products By Molecule: semaglutide dulaglutide tirzepatide cagrilintide semaglutide combination survodutide orforglipron retatrutide other molecules By Type: Patented Biosimilars By Format: Single-dose Multi-dose Tablets By Indication: Diabetes Obesity Other Indications By Route of administration: Subcutaneous Oral By End User: Home Care Settings and Fitness/ Weight Management Facilities Long-term Care Facilities and Hospitals & Specialty Clinics
Regions Covered	North America, Europe, Asia Pacific, Latin America, the Middle East & Africa

WHAT IS IN IT FOR YOU: GLP-1 Agonists Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Asia Pacific GLP-1 Agonists Landscape	Detailed company profiles of competitors (financials (public companies), product (patented and biosimilars portfolio) Customer landscape mapping by end-use sector Pipeline analysis	Identify interconnections and supply chain blind spots Detect customer migration trends across industries Highlight untapped customer clusters for market entry

RECENT DEVELOPMENTS

September 2025 : Novo Nordisk (Denmark) received EU approval for its oral GLP-1 receptor agonist drug, Rybelsus, to reduce cardiovascular death, heart attack, and stroke. It is the first and only oral GLP-1 agonist drug to receive this indication approval in the EU.
August 2025 : The US FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity.
March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD.
November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

RESEARCH METHODOLOGY

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

Pharmaceutical giants fuel GLP-1 market expansion, driven by obesity prevalence and innovative oral treatments.

5.1

INTRODUCTION

5.2

MARKET DYNAMICS

5.2.1

DRIVERS

5.2.1.1

EXPANDING MANUFACTURING CAPACITIES OF LARGE PHARMACEUTICAL COMPANIES

5.2.1.2

SHIFT OF GLP-1 DRUGS FROM DIABETES SPECIALTY TO BROADER TREATMENT OPTIONS

5.2.1.3

RISING PREVALENCE OF OBESITY AND TYPE-2 DIABETES

5.2.2

RESTRAINTS

5.2.2.1

STRINGENT COST AND PAYER CONTROLS

5.2.3

OPPORTUNITIES

5.2.3.1

INCREASING STUDIES ON ORAL GLP-1

5.2.4

CHALLENGES

5.2.4.1

COUNTERFEITS AND COMPOUNDED GLP-1 GRAY MARKET

5.2.4.2

SAFETY, TOLERABILITY, AND PERSISTENCE ISSUES

5.3

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

5.3.1

KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES

5.4

PRICING ANALYSIS

5.4.1

AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024

5.4.2

AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024

5.4.3

AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024

5.4.4

FACTORS IMPACTING GLP-1 AGONISTS PRICING

5.5

INDUSTRY TRENDS

5.5.1

SHIFT OF WEEKLY INJECTABLES TOWARD ORALS AND MULTI-AGONISTS

5.5.2

VERTICAL INTEGRATION AND CAPACITY SCALE-UP TO MEET DEMAND

5.6

TECHNOLOGY ANALYSIS

5.6.1

KEY TECHNOLOGIES

5.6.1.1

CHEMICAL SYNTHESIS

5.6.1.2

RECOMBINANT DNA TECHNOLOGY

5.6.2

COMPLEMENTARY TECHNOLOGIES

5.6.2.1

PEPTELLIGENCE

5.6.2.2

PEGYLATION AND POLYMER ENCAPSULATION

5.6.3

ADJACENT TECHNOLOGIES

5.6.3.1

HYDROGEL DEPOT TECHNOLOGIES

5.6.3.2

TECHNOLOGIES FOR ORAL DELIVERY OF GLP-1 ANALOGUES

5.7

PIPELINE ANALYSIS

5.8

TECHNOLOGY/PRODUCT ROADMAP

5.9

VALUE CHAIN ANALYSIS

5.10

ECOSYSTEM ANALYSIS

5.10.1

ROLE IN ECOSYSTEM

5.11

PORTER’S FIVE FORCES ANALYSIS

5.11.1

THREAT OF NEW ENTRANTS

5.11.2

THREAT OF SUBSTITUTES

5.11.3

BARGAINING POWER OF SUPPLIERS

5.11.4

BARGAINING POWER OF BUYERS

5.11.5

INTENSITY OF COMPETITIVE RIVALRY

5.12

REGULATORY ANALYSIS

5.12.1

REGULATORY LANDSCAPE

5.12.2

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.13

KEY CONFERENCES & EVENTS, 2025–2026

5.14

CUSTOMER LANDSCAPE & BUYER BEHAVIOR

5.14.1

KEY STAKEHOLDERS IN BUYING PROCESS

5.14.2

KEY BUYING CRITERIA

5.14.3

ADOPTION BARRIER & INTERNAL FRICTION

5.15

INVESTMENT/FUNDING SCENARIO

5.16

REIMBURSEMENT SCENARIO

5.17

IMPACT OF AI/GEN AI ON GLP-1 AGONISTS MARKET

5.17.1

IMPACT AT DEVELOPMENT AND MANUFACTURING STAGES

5.17.2

AI USE CASES

5.17.3

KEY COMPANIES IMPLEMENTING AI

5.17.4

FUTURE OF AI/GEN AI IN GLP-1 AGONIST DRUG DEVELOPMENT ECOSYSTEM

5.18

IMPACT OF 2025 TRUMP TARIFF ON GLP-1 AGONISTS MARKET

5.18.1

INTRODUCTION

5.18.2

KEY TARIFF RATES

5.18.3

PRICE IMPACT ANALYSIS

5.18.4

IMPACT ON REGION

5.18.4.1

NORTH AMERICA

5.18.4.2

EUROPE

5.18.4.3

ASIA PACIFIC

5.18.5

IMPACT ON END-USE INDUSTRIES

5.18.5.1

HOSPITALS & SPECIALTY CENTERS

5.18.5.2

LONG-TERM CARE FACILITIES

GLP-1 AGONISTS MARKET, BY PRODUCT

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion and Units | 91 Data Tables

111

6.1

INTRODUCTION

6.2

GLP-1 AGONISTS VOLUME MARKET ESTIMATION

6.3

OZEMPIC

6.3.1

ANTICIPATED PATENT EXPIRY OF SEMAGLUTIDE STARTING IN 2026 AND EXPECTED NEW DRUG LAUNCHES TO NEGATIVELY IMPACT MARKET

6.4

TRULICITY

6.4.1

LOSS OF PATENT EXCLUSIVITY AND HIGH COMPETITIVE PRESSURE TO DISRUPT MARKET GROWTH

6.5

MOUNJARO

6.5.1

DUAL MECHANISM AS BOTH GIP AND GLP-1 RECEPTOR AGONIST TO PROPEL ADOPTION

6.6

WEGOVY

6.6.1

INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT MARKET GROWTH

6.7

RYBELSUS

6.7.1

EASE OF ADMINISTRATION TO FUEL ADOPTION AMONG PATIENTS

6.8

ZEPBOUND

6.8.1

INCREASED FOCUS ON OBESITY MANAGEMENT TO INDICATE HUGE GROWTH POTENTIAL

6.9

ORFORGLIPRON

6.9.1

ORFORGLIPRON TO GAIN HIGH POTENTIAL DUE TO DEVICE-FREE LOGISTICS AND NO FASTING WINDOW

6.10

CAGRISEMA

6.10.1

FOCUS ON CHRONIC WEIGHT MANAGEMENT AND TYPE 2 DIABETES TREATMENT TO SPUR MARKET GROWTH

6.11

SURVODUTIDE

6.11.1

STRONG CLINICAL EFFICACY IN OBESITY AND METABOLIC DISEASE MANAGEMENT TO AID MARKET GROWTH

6.12

RETATRUTIDE

6.12.1

STRONG WEIGHT-LOSS SIGNALS IN PHASE-2 DIABETES AND GLOBAL PHASE-3 CLINICAL PIPELINE TO DRIVE MARKET

6.13

SEMAGLUTIDE BIOSIMILARS

6.13.1

HIGH DEMAND FOR AFFORDABLE DIABETES AND OBESITY TREATMENTS TO AID GROWTH

6.14

OTHER GLP-1 BIOSIMILARS

6.15

OTHER PRODUCTS

GLP-1 AGONISTS MARKET, BY MOLECULE

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion | 57 Data Tables

155

7.1

INTRODUCTION

7.2

SEMAGLUTIDE

7.2.1

PROVEN EFFICACY IN SIGNIFICANT WEIGHT LOSS AND GLYCEMIC CONTROL TO SUPPORT GROWTH

7.3

TIRZEPATIDE

7.3.1

STRONG EFFECTIVENESS IN OBESITY TREATMENT TO ENHANCE PHYSICIAN CONFIDENCE AND PAYER INTEREST

7.4

DULAGLUTIDE

7.4.1

USAGE IN PEDIATRIC TYPE 2 DIABETES FOR PATIENTS OVER 10 YEARS OLD TO ENHANCE USAGE IN SPECIALTY SETTINGS

7.5

CAGRILINTIDE SEMAGLUTIDE COMBINATION

7.5.1

SIGNIFICANT CLINICAL OUTCOMES IN WEIGHT MANAGEMENT TO DRIVE MARKET GROWTH

7.6

ORFORGLIPRON

7.6.1

NEEDLE-FREE ALTERNATIVE TO INCREASE CONVENIENCE AND SUPPORT ADOPTION AMONG PATIENTS

7.7

SURVODUTIDE

7.7.1

DUAL GCG/GLP-1 RECEPTOR AGONISM AND FAVORABLE CLINICAL EVIDENCE TO AID GROWTH

7.8

RETATRUTIDE

7.8.1

TRIPLE-AGONIST APPROACH AND BEST-IN-CLASS WEIGHT MANAGEMENT FOR OBESITY TO SHOW HIGH GROWTH POTENTIAL

7.9

OTHER MOLECULES

GLP-1 AGONISTS MARKET, BY TYPE

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion | 30 Data Tables

184

8.1

INTRODUCTION

8.2

PATENTED PRODUCTS

8.2.1

PATENTED GLP-1 BRANDS TO SHIFT FROM WEIGHT LOSS DRUGS TO CARDIOMETABOLIC THERAPIES FOR BETTER ACCESS AND DURABILITY

8.3

BIOSIMILARS

8.3.1

SEMAGLUTIDE BIOSIMILARS

8.3.1.1

UPCOMING PATENT EXPIRY FOR MAJOR DRUGS IN KEY MARKETS TO INCREASE BIOSIMILAR ADOPTION

8.3.2

OTHER BIOSIMILARS

GLP-1 AGONISTS MARKET, BY INDICATION

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion | 22 Data Tables

200

9.1

INTRODUCTIONS

9.2

DIABETES

9.2.1

HIGH DIABETES PREVALENCE TO FUEL MARKET ADOPTION

9.3

OBESITY

9.3.1

STRONG PIPELINE OF ANTI-OBESITY GLP-1 DRUGS TO DRIVE MARKET

9.4

OTHER INDICATIONS

GLP-1 AGONISTS MARKET, BY FORMAT

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion | 22 Data Tables

211

10.1

INTRODUCTION

10.2

SINGLE-DOSE FORMATS

10.2.1

EASE OF ADMINISTRATION, DOSING AMOUNT PRECISION, AND LOW CONTAMINATION RISK TO SUPPORT MARKET GROWTH

10.3

MULTI-DOSE FORMATS

10.3.1

COST-EFFECTIVENESS AND LOW MEDICAL WASTE GENERATION TO AUGMENT ADOPTION IN HEALTHCARE SETTINGS

10.4

AUTOINJECTORS

10.4.1

SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION

GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion | 30 Data Tables

223

11.1

INTRODUCTION

11.2

SUBCUTANEOUS ADMINISTRATION

11.2.1

PEN INJECTORS

11.2.1.1

EASY MONITORING OF VOLUME AND DOSAGE STRENGTH TO SUPPORT ADOPTION

11.2.2

AUTOINJECTORS

11.2.2.1

SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION

11.3

ORAL ADMINISTRATION

11.3.1

ELIMINATION OF NEEDLEPHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

GLP-1 AGONISTS MARKET, BY END USER

Market Size & Growth Rate Forecast Analysis to 2033 in USD Billion | 22 Data Tables

237

12.1

INTRODUCTION

12.2

HOME CARE SETTINGS AND FITNESS/ WEIGHT MANAGEMENT FACILITIES

12.2.1

RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH

12.3

LONG-TERM CARE FACILITIES

12.3.1

GROWING GERIATRIC POPULATION WITH CHRONIC DISEASES TO SUPPORT SEGMENT GROWTH

12.4

HOSPITALS & SPECIALTY CLINICS

12.4.1

ORGANIZED ENVIRONMENT, PROFESSIONAL OVERSIGHT, AND ABILITY TO HANDLE COMPLEX PATIENT NEEDS TO DRIVE MARKET

GLP-1 AGONISTS MARKET, BY REGION

Comprehensive coverage of 7 Regions with country-level deep-dive of 17 Countries | 274 Data Tables.

249

13.1

INTRODUCTION

13.2

NORTH AMERICA

13.2.1

MACROECONOMIC OUTLOOK FOR NORTH AMERICA

13.2.2

13.2.2.1

US TO DOMINATE NORTH AMERICAN GLP-1 AGONISTS MARKET DURING FORECAST PERIOD

13.2.3

CANADA

13.2.3.1

FAVORABLE FUNDING SCENARIO AND PRESENCE OF STRONG RESEARCH INFRASTRUCTURE TO SUPPORT MARKET GROWTH

13.3

EUROPE

13.3.1

MACROECONOMIC OUTLOOK FOR EUROPE

13.3.2

GERMANY

13.3.2.1

EXPERTISE IN BIOTECHNOLOGY AND REPUTATION AS LEADING PHARMACEUTICAL MANUFACTURING HUB TO EXPEDITE MARKET GROWTH

13.3.3

13.3.3.1

GROWING R&D INITIATIVES FOR DEVELOPMENT OF GLP-1 AGONISTS DRUGS TO SUPPORT MARKET GROWTH

13.3.4

FRANCE

13.3.4.1

FAVORABLE REGULATORY SCENARIO AND STRONG RESEARCH INFRASTRUCTURE TO PROPEL MARKET GROWTH

13.3.5

ITALY

13.3.5.1

PRESENCE OF KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH

13.3.6

SPAIN

13.3.6.1

HIGH INCIDENCE OF DIABETES AND OBESITY TO AUGMENT MARKET ADOPTION OF GLP-1 THERAPEUTIC DRUGS

13.3.7

NETHERLANDS

13.3.7.1

STRONG FOCUS ON PHARMACEUTICAL R&D TO SUPPORT MARKET GROWTH

13.3.8

REST OF EUROPE

13.4

ASIA PACIFIC

13.4.1

MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

13.4.2

CHINA

13.4.2.1

INCREASING ENDORSEMENTS OF ANTI-OBESITY DRUGS BY CELEBRITIES TO DRIVE MARKET ADOPTION

13.4.3

JAPAN

13.4.3.1

HIGH DIABETIC POPULATION AND FAVORABLE REGULATORY SCENARIO TO AID MARKET GROWTH

13.4.4

INDIA

13.4.4.1

GROWING DEMAND FOR COST-EFFECTIVE AND ACCESSIBLE ANTI-OBESITY MEDICATIONS TO AID MARKET GROWTH

13.4.5

AUSTRALIA

13.4.5.1

SIGNIFICANT GOVERNMENT INVESTMENT IN OBESITY PREVENTION TO FUEL MARKET GROWTH

13.4.6

SOUTH KOREA

13.4.6.1

INCREASING STRATEGIC COLLABORATIONS IN OBESITY DRUGS TO PROPEL MARKET GROWTH

13.4.7

REST OF ASIA PACIFIC

13.5

LATIN AMERICA

13.5.1

MACROECONOMIC OUTLOOK FOR LATIN AMERICA

13.5.2

BRAZIL

13.5.2.1

INCREASING PARTNERSHIPS WITH GLOBAL PHARMACEUTICAL COMPANIES AND RISING DIABETES CASES TO DRIVE BRAZILIAN MARKET

13.5.3

MEXICO

13.5.3.1

GROWING DIABETES AND OBESITY PREVALENCE TO SUPPORT MARKET GROWTH

13.5.4

REST OF LATIN AMERICA

13.6

MIDDLE EAST

13.6.1

MACROECONOMIC OUTLOOK FOR MIDDLE EAST

13.6.2

GCC COUNTRIES

13.6.2.1

KINGDOM OF SAUDI ARABIA

13.6.2.2

UAE

13.6.2.3

REST OF GCC COUNTRIES

13.6.3

REST OF MIDDLE EAST

13.7

AFRICA

13.7.1

GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH

13.7.2

MACROECONOMIC OUTLOOK FOR AFRICA

COMPETITIVE LANDSCAPE

Discover emerging leaders and strategic shifts shaping the GLP-1 agonists market dominance.

375

14.1

INTRODUCTION

14.2

KEY STRATEGIES/RIGHT TO WIN

14.2.1

OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET

14.3

REVENUE ANALYSIS, 2020–2024

14.4

MARKET SHARE ANALYSIS, 2024

14.5

COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

14.5.1

STARS

14.5.2

EMERGING LEADERS

14.5.3

PERVASIVE PLAYERS

14.5.4

PARTICIPANTS

14.6

COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024

14.6.1

STARS

14.6.2

EMERGING LEADERS

14.6.3

PERVASIVE PLAYERS

14.6.4

PARTICIPANTS

14.6.5

COMPANY FOOTPRINT: KEY PLAYERS, 2024

14.6.5.1

COMPANY FOOTPRINT

14.6.5.2

REGION FOOTPRINT

14.6.5.3

FORMAT FOOTPRINT

14.6.5.4

ROUTE OF ADMINISTRATION FOOTPRINT

14.6.5.5

INDICATION FOOTPRINT

14.7

COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

14.7.1

PROGRESSIVE COMPANIES

14.7.2

RESPONSIVE COMPANIES

14.7.3

DYNAMIC COMPANIES

14.7.4

STARTING BLOCKS

14.7.5

COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

14.7.5.1

COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

14.8

COMPANY VALUATION & FINANCIAL METRICS

14.8.1

FINANCIAL METRICS

14.8.2

COMPANY VALUATION

14.9

BRAND/PRODUCT COMPARISON

14.10

COMPETITIVE SCENARIO

14.10.1

PRODUCT APPROVALS

14.10.2

DEALS

14.10.3

EXPANSIONS

14.10.4

OTHER DEVELOPMENTS

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

396

15.1

INTRODUCTION

15.2

KEY PLAYERS

15.2.1

NOVO NORDISK A/S

15.2.1.1

BUSINESS OVERVIEW

15.2.1.2

PRODUCTS OFFERED

15.2.1.3

RECENT DEVELOPMENTS

15.2.1.4

MNM VIEW

15.2.2

ELI LILLY AND COMPANY

15.2.3

SANOFI

15.2.4

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

15.2.5

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

15.2.6

INNOVENT

15.2.7

PEGBIO CO., LTD.

15.2.8

SCIWIND BIOSCIENCES CO., LTD.

15.2.9

ZEALAND PHARMA

15.2.10

STRUCTURE THERAPEUTICS, INC.

15.2.11

VIKING THERAPEUTICS

15.2.12

SUN PHARMACEUTICAL INDUSTRIES LTD.

15.2.13

VTV THERAPEUTICS

15.2.14

ALTIMMUNE

15.2.15

AMGEN INC.

15.2.16

GLENMARK PHARMACEUTICALS LTD.

15.2.17

BIOCON

15.2.18

TEVA PHARMACEUTICAL INDUSTRIES LTD.

15.2.19

F. HOFFMANN-LA ROCHE LTD.

15.3

OTHER PLAYERS

15.3.1

TERNS PHARMACEUTICALS, INC.

15.3.2

METAVIA

15.3.3

SCOHIA PHARMA, INC.

15.3.4

REGOR THERAPEUTICS GROUP

15.3.5

NEURALY INC.

15.3.6

I2O THERAPEUTICS, INC.

15.3.7

PFIZER INC.

15.3.8

HANMI PHARM CO.,LTD.

15.3.9

JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

15.3.10

BIOMED INDUSTRIES, INC.

APPENDIX

448

16.1

DISCUSSION GUIDE

16.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

16.3

CUSTOMIZATION OPTIONS

16.4

RELATED REPORTS

16.5

AUTHOR DETAILS

LIST OF TABLES

TABLE 1

GLP-1 AGONISTS MARKET: INCLUSIONS & EXCLUSIONS

TABLE 2

GLP-1 AGONISTS MARKET: RISK ANALYSIS

TABLE 3

GLP-1 AGONISTS MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES

TABLE 4

GLP-1 AGONISTS MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS

TABLE 5

EXPECTED KEY LAUNCHES IN GLP-1 AGONISTS MARKET, 2025–2033

TABLE 6

GLP-1 AGONISTS MARKET: IMPACT ANALYSIS

TABLE 7

KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES

TABLE 8

AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)

TABLE 9

AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024 (USD)

TABLE 10

GLP-1 AGONISTS IN CLINICAL PIPELINE (AS OF SEPTEMBER 2025)

TABLE 11

GLP-1 AGONISTS MARKET: ROLE IN ECOSYSTEM

TABLE 12

GLP-1 AGONISTS MARKET: PORTER’S FIVE FORCES

TABLE 13

NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14

EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15

ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16

REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17

LIST OF KEY CONFERENCES & EVENTS IN GLP-1 AGONISTS MARKET, JANUARY 2025–DECEMBER 2026

TABLE 18

INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE

TABLE 19

BUYING CRITERIA FOR GLP-1 AGONIST PRODUCTS, BY END USER

TABLE 20

GLP-1 AGONISTS: ADOPTION BARRIER & INTERNAL FRICTION

TABLE 21

KEY COMPANIES IMPLEMENTING AI IN GLP-1 AGONISTS MARKET

TABLE 22

GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 23

GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (MILLION UNITS)

TABLE 24

GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION)

TABLE 25

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 26

EUROPE: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 27

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 28

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 29

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION)

TABLE 30

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 31

GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 32

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 33

EUROPE: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 34

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 35

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 36

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 37

GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024–2033 (USD BILLION)

TABLE 38

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 39

EUROPE: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 40

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 41

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 42

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024–2033 (USD BILLION)

TABLE 43

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 44

GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION)

TABLE 45

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 46

EUROPE: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 47

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 48

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 49

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION)

TABLE 50

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 51

GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION)

TABLE 52

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 53

EUROPE: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 54

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 55

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 56

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION)

TABLE 57

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 58

GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024–2033 (USD BILLION)

TABLE 59

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, S2024–2033 (USD BILLION)

TABLE 60

EUROPE: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 61

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 62

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 63

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024–2033 (USD BILLION)

TABLE 64

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 65

GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 66

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 67

EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 68

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 69

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 70

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 71

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 72

GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024–2033 (USD BILLION)

TABLE 73

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 74

EUROPE: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 75

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 76

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 77

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024–2033 (USD BILLION)

TABLE 78

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 79

GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 80

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 81

EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 82

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 83

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 84

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 85

GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 86

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 87

EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 88

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 89

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 90

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 91

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 92

GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 93

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 94

EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 95

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 96

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 97

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 98

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 99

GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 100

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 101

EUROPE: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 102

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 103

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 104

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 105

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 106

GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION)

TABLE 107

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 108

EUROPE: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 109

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 110

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 111

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION)

TABLE 112

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 113

GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 114

GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 115

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 116

EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 117

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 118

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 119

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 120

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 121

GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 122

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 123

EUROPE: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 124

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 125

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 126

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 127

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 128

GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 129

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 130

EUROPE: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 131

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 132

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 133

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 134

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 135

GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 136

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 137

EUROPE: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 138

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 139

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 140

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 141

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 142

GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 143

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 144

EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 145

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 146

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 147

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 148

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 149

GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 150

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 151

EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 152

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 153

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 154

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 155

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 156

GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 157

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 158

EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 159

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 160

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 161

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 162

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 163

GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION)

TABLE 164

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 165

EUROPE: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 166

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 167

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 168

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION)

TABLE 169

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 170

GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 171

GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION)

TABLE 172

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 173

EUROPE: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 174

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 175

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 176

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION)

TABLE 177

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 178

GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 179

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 180

EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 181

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 182

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 183

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 184

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 185

GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 186

SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 187

NORTH AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 188

EUROPE: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 189

ASIA PACIFIC: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 190

LATIN AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 191

MIDDLE EAST: SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 192

GCC COUNTRIES: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 193

OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 194

NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 195

EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 196

ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 197

LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 198

MIDDLE EAST: OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 199

GCC COUNTRIES: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 200

GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 201

GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION)

TABLE 202

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 203

EUROPE: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 204

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 205

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 206

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION)

TABLE 207

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 208

GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 209

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 210

EUROPE: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 211

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 212

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 213

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 214

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 215

GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION)

TABLE 216

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 217

EUROPE: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 218

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 219

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 220

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION)

TABLE 221

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 222

GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 223

GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 224

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 225

EUROPE: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 226

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 227

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 228

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 229

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 230

GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 231

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 232

EUROPE: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 233

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 234

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 235

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 236

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 237

GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION)

TABLE 238

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 239

EUROPE: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 240

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 241

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 242

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION)

TABLE 243

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 244

GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 245

GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 246

GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 247

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 248

EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 249

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 250

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 251

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 252

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 253

PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 254

NORTH AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 255

EUROPE: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 256

ASIA PACIFIC: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 257

LATIN AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 258

MIDDLE EAST: PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 259

GCC COUNTRIES: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 260

AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 261

NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 262

EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 263

ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 264

LATIN AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 265

MIDDLE EAST: AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 266

GCC COUNTRIES: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 267

GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 268

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 269

EUROPE: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 270

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 271

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 272

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 273

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 274

GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 275

GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 276

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 277

EUROPE: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 278

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 279

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 280

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 281

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 282

GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 283

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 284

EUROPE: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 285

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 286

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 287

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 288

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 289

GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION)

TABLE 290

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 291

EUROPE: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 292

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 293

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 294

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION)

TABLE 295

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 296

GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 297

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 298

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 299

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 300

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 301

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 302

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 303

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 304

NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 305

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 306

NORTH AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 307

NORTH AMERICA: KEY MACROINDICATORS

TABLE 308

US: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 309

US: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 310

US: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 311

US: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 312

US: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 313

US: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 314

US: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 315

US: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 316

US: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 317

CANADA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 318

CANADA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 319

CANADA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 320

CANADA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 321

CANADA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 322

CANADA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 323

CANADA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 324

CANADA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 325

CANADA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 326

EUROPE: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 327

EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 328

EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 329

EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 330

EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 331

EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 332

EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 333

EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 334

EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 335

EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 336

EUROPE: KEY MACROINDICATORS

TABLE 337

GERMANY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 338

GERMANY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 339

GERMANY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 340

GERMANY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 341

GERMANY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 342

GERMANY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 343

GERMANY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 344

GERMANY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 345

GERMANY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 346

UK: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 347

UK: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 348

UK: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 349

UK: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 350

UK: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 351

UK: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 352

UK: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 353

UK: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 354

UK: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 355

FRANCE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 356

FRANCE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 357

FRANCE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 358

FRANCE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 359

FRANCE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 360

FRANCE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 361

FRANCE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 362

FRANCE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 363

FRANCE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 364

ITALY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 365

ITALY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 366

ITALY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 367

ITALY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 368

ITALY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 369

ITALY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 370

ITALY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 371

ITALY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 372

ITALY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 373

SPAIN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 374

SPAIN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 375

SPAIN: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 376

SPAIN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 377

SPAIN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 378

SPAIN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 379

SPAIN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 380

SPAIN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 381

SPAIN: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 382

NETHERLANDS: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 383

NETHERLANDS: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 384

NETHERLANDS: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 385

NETHERLANDS: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 386

NETHERLANDS: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 387

NETHERLANDS: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 388

NETHERLANDS: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 389

NETHERLANDS: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 390

NETHERLANDS: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 391

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 392

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 393

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 394

REST OF EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 395

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 396

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 397

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 398

REST OF EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 399

REST OF EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 400

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 401

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 402

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 403

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 404

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 405

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 406

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 407

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 408

ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 409

ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 410

ASIA PACIFIC: KEY MACROINDICATORS

TABLE 411

CHINA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 412

CHINA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 413

CHINA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 414

CHINA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 415

CHINA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 416

CHINA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 417

CHINA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 418

CHINA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 419

CHINA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 420

JAPAN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 421

JAPAN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 422

JAPAN: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 423

JAPAN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 424

JAPAN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 425

JAPAN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 426

JAPAN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 427

JAPAN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 428

JAPAN: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 429

INDIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 430

INDIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 431

INDIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 432

INDIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 433

INDIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 434

INDIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 435

INDIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 436

INDIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 437

INDIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 438

AUSTRALIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 439

AUSTRALIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 440

AUSTRALIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 441

AUSTRALIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 442

AUSTRALIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 443

AUSTRALIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 444

AUSTRALIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 445

AUSTRALIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 446

AUSTRALIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 447

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 448

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 449

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 450

SOUTH KOREA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 451

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 452

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 453

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 454

SOUTH KOREA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 455

SOUTH KOREA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 456

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 457

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 458

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 459

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 460

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 461

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 462

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 463

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 464

REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 465

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 466

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 467

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 468

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 469

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 470

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 471

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 472

LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 473

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 474

LATIN AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 475

LATIN AMERICA: KEY MACROINDICATORS

TABLE 476

BRAZIL: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 477

BRAZIL: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 478

BRAZIL: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 479

BRAZIL: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 480

BRAZIL: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 481

BRAZIL: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 482

BRAZIL: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 483

BRAZIL: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 484

BRAZIL: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 485

MEXICO: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 486

MEXICO: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 487

MEXICO: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 488

MEXICO: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 489

MEXICO: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 490

MEXICO: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 491

MEXICO: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 492

MEXICO: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 493

MEXICO: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 494

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 495

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 496

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 497

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 498

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 499

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 500

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 501

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 502

REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 503

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 504

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 505

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 506

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 507

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 508

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 509

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 510

MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 511

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 512

MIDDLE EAST: GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 513

MIDDLE EAST: KEY MACROINDICATORS

TABLE 514

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 515

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 516

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 517

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 518

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 519

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 520

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 521

GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 522

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 523

GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 524

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 525

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 526

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 527

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 528

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 529

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 530

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 531

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 532

KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 533

UAE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 534

UAE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 535

UAE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 536

UAE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 537

UAE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 538

UAE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 539

UAE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 540

UAE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 541

UAE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 542

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 543

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 544

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 545

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 546

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 547

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 548

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 549

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 550

REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 551

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 552

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 553

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 554

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 555

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 556

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 557

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 558

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 559

REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 560

AFRICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 561

AFRICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 562

AFRICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 563

AFRICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 564

AFRICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 565

AFRICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 566

AFRICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 567

AFRICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 568

AFRICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 569

AFRICA: KEY MACROINDICATORS

TABLE 570

OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN GLP-1 AGONISTS MARKET

TABLE 571

GLP-1 AGONISTS MARKET: DEGREE OF COMPETITION

TABLE 572

GLP-1 AGONISTS MARKET: REGION FOOTPRINT (KEY PLAYERS)

TABLE 573

GLP-1 AGONISTS MARKET: REGION FOOTPRINT (PRODUCTS IN PIPELINE)

TABLE 574

GLP-1 AGONISTS MARKET: FORMAT FOOTPRINT

TABLE 575

GLP-1 AGONISTS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT

TABLE 576

GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (KEY PLAYERS)

TABLE 577

GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (PRODUCTS IN PIPELINE)

TABLE 578

GLP-1 AGONISTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS

TABLE 579

GLP-1 AGONISTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY INDICATION AND REGION

TABLE 580

GLP-1 AGONISTS MARKET: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025

TABLE 581

GLP-1 AGONISTS MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 582

GLP-1 AGONISTS MARKET: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025

TABLE 583

GLP-1 AGONISTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 584

NOVO NORDISK A/S: COMPANY OVERVIEW

TABLE 585

NOVO NORDISK A/S: PRODUCTS OFFERED

TABLE 586

NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025

TABLE 587

NOVO NORDISK A/S: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 588

NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025

TABLE 589

NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 590

ELI LILLY AND COMPANY: COMPANY OVERVIEW

TABLE 591

ELI LILLY AND COMPANY: PRODUCTS OFFERED

TABLE 592

ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025

TABLE 593

ELI LILLY AND COMPANY: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 594

ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025

TABLE 595

SANOFI: COMPANY OVERVIEW

TABLE 596

SANOFI: PRODUCTS OFFERED

TABLE 597

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY OVERVIEW

TABLE 598

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: PRODUCTS OFFERED

TABLE 599

BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW

TABLE 600

BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED (IN PIPELINE)

TABLE 601

BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 602

INNOVENT: COMPANY OVERVIEW

TABLE 603

INNOVENT: PRODUCTS OFFERED (IN PIPELINE)

TABLE 604

INNOVENT: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025

TABLE 605

INNOVENT: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 606

PEGBIO CO., LTD.: COMPANY OVERVIEW

TABLE 607

PEGBIO CO., LTD.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 608

SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW

TABLE 609

SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 610

SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 611

SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 612

ZEALAND PHARMA: COMPANY OVERVIEW

TABLE 613

ZEALAND PHARMA: PRODUCTS OFFERED (IN PIPELINE)

TABLE 614

ZEALAND PHARMA: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 615

ZEALAND PHARMA: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 616

STRUCTURE THERAPEUTICS, INC.: COMPANY OVERVIEW

TABLE 617

STRUCTURE THERAPEUTICS, INC.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 618

STRUCTURE THERAPEUTICS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 619

VIKING THERAPEUTICS: COMPANY OVERVIEW

TABLE 620

VIKING THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE)

TABLE 621

VIKING THERAPEUTICS: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 622

SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW

TABLE 623

SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 624

VTV THERAPEUTICS: COMPANY OVERVIEW

TABLE 625

VTV THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE)

TABLE 626

ALTIMMUNE: COMPANY OVERVIEW

TABLE 627

ALTIMMUNE: PRODUCTS OFFERED (IN PIPELINE)

TABLE 628

ALTIMMUNE: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025

TABLE 629

AMGEN INC.: COMPANY OVERVIEW

TABLE 630

AMGEN INC.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 631

GLENMARK PHARMACEUTICALS LTD.: COMPANY OVERVIEW

TABLE 632

GLENMARK PHARMACEUTICALS LTD.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 633

GLENMARK PHARMACEUTICALS LTD.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025

TABLE 634

BIOCON: COMPANY OVERVIEW

TABLE 635

BIOCON: PRODUCTS OFFERED (IN PIPELINE)

TABLE 636

BIOCON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025

TABLE 637

BIOCON: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 638

TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW

TABLE 639

TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED (IN PIPELINE)

TABLE 640

TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025

TABLE 641

F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW

TABLE 642

F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED (IN PIPELINE)

TABLE 643

F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025

TABLE 644

TERNS PHARMACEUTICALS, INC.: COMPANY OVERVIEW

TABLE 645

METAVIA: COMPANY OVERVIEW

TABLE 646

SCOHIA PHARMA, INC.: COMPANY OVERVIEW

TABLE 647

REGOR THERAPEUTICS GROUP: COMPANY OVERVIEW

TABLE 648

NEURALY INC.: COMPANY OVERVIEW

TABLE 649

I2O THERAPEUTICS, INC.: COMPANY OVERVIEW

TABLE 650

PFIZER INC.: COMPANY OVERVIEW

TABLE 651

HANMI PHARM CO., LTD.: COMPANY OVERVIEW

TABLE 652

JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW

TABLE 653

BIOMED INDUSTRIES, INC.: COMPANY OVERVIEW

LIST OF FIGURES

FIGURE 1

GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2

GLP-1 AGONISTS MARKET: YEARS CONSIDERED

FIGURE 3

GLP-1 AGONISTS MARKET: RESEARCH DESIGN

FIGURE 4

BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS

FIGURE 5

GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 6

GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024

FIGURE 7

MARKET VALIDATION FROM PRIMARY EXPERTS

FIGURE 8

GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

FIGURE 9

CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 2025–2033

FIGURE 10

GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET

FIGURE 11

GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY

FIGURE 12

GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS. 2033 (USD BILLION)

FIGURE 13

GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2033 (USD BILLION)

FIGURE 14

GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS. 2030 (USD BILLION)

FIGURE 15

GLP-1 AGONISTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)

FIGURE 16

REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET

FIGURE 17

INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY TO PROPEL MARKET GROWTH

FIGURE 18

US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024

FIGURE 19

SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024

FIGURE 20

HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024

FIGURE 21

KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 22

GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 23

US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)

FIGURE 24

GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

FIGURE 25

AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)

FIGURE 26

GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS

FIGURE 27

GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS

FIGURE 28

GLP-1 AGONISTS MARKET: PORTER’S FIVE FORCES ANALYSIS

FIGURE 29

INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS, BY TYPE

FIGURE 30

KEY BUYING CRITERIA FOR END USERS

FIGURE 31

AI USE CASES IN GLP-1 AGONISTS MARKET

FIGURE 32

NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT

FIGURE 33

ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT

FIGURE 34

REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET, 2020–2024 (USD BILLION)

FIGURE 35

MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024)

FIGURE 36

GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 37

GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024

FIGURE 38

GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS)

FIGURE 39

GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE)

FIGURE 40

GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 41

EV/EBITDA OF KEY VENDORS

FIGURE 42

YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 43

GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 44

NOVO NORDISK A/S: COMPANY SNAPSHOT

FIGURE 45

ELI LILLY AND COMPANY: COMPANY SNAPSHOT

FIGURE 46

SANOFI: COMPANY SNAPSHOT

FIGURE 47

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT

FIGURE 48

BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT

FIGURE 49

INNOVENT: COMPANY SNAPSHOT

FIGURE 50

ZEALAND PHARMA: COMPANY SNAPSHOT

FIGURE 51

SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

FIGURE 52

AMGEN INC.: COMPANY SNAPSHOT

FIGURE 53

GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT

FIGURE 54

BIOCON: COMPANY SNAPSHOT

FIGURE 55

TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

FIGURE 56

F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

Methodology

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global GLP-1 agonists market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The market for the companies offering GLP-1 agonists is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, their revenue mapping, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global GLP-1 agonists market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global GLP-1 agonists market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, as well as trial managers. These interviews were conducted across major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the GLP-1 agonists market. These methods were also used extensively to estimate the size of various subsegments in the market.

A bottom-up approach was used to estimate and validate the total size of the GLP-1 Agonists market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The list of approved GLP-1 agonists was identified through extensive secondary and primary research.
The revenues generated from these GLP-1 Agonists have been determined through annual reports and secondary sources (including paid databases)

The products were mapped according to the market segments. Percentage shares and splits were determined based on the revenue contributed to each of the segments. This was verified using secondary sources and by industry experts.

Bottom-up Approach and Top-down Approach

The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process.

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Glucagon-like peptide 1 (GLP-1) agonists, alternatively termed GLP-1 receptor agonists, are drugs designed to mimic the incretin hormone glucagon-like peptide-1 (GLP-1). These drugs are primarily used for the treatment of type 2 diabetes mellitus and, more recently, obesity. They stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying, which aids in lowering blood sugar levels and promotes satiety. This market is for these GLP-1 agonists administered as a single drug or in combination with other receptor agonists, such as insulin.

Stakeholders

Pharmaceutical & Biotechnology Companies
Hospitals
Specialty Clinics
Long-term Care Facilities
Academic Researchers and Government Research Organizations
Private Research Institutes
Contract Manufacturing Organizations (CMOs)
Contract Research Organizations (CROs)
Venture Capitalists

Report Objectives

To define, describe, and forecast the GLP-1 agonists market by product, molecule, type, format, route of administration, indications, end user, and region
To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall GLP-1 agonists market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To profile the key players in the global GLP-1 agonists market and comprehensively analyze their core competencies and market rankings
To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
To forecast the volume of key products (anti-obesity medicines)
To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the GLP-1 agonists market

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033

OVERVIEW

KEY TAKEAWAYS

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

MARKET DYNAMICS

Driver: Expanding manufacturing capacity

Restraint: Stringent cost and payer controls

Opportunity: Increasing studies on oral GLP-1

Challenge: Counterfeits and compounded GLP-1 gray market

GLP-1 Agonists Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

MARKET ECOSYSTEM

MARKET SEGMENTS

GLP-1 Agonists Market, By Product

GLP-1 Agonists Market, By Indication

GLP-1 Agonists Market, By End User

REGION

North America to be the fastest-growing region in the global GLP-1 agonists market during the forecast period

GLP-1 Agonists Market: COMPANY EVALUATION MATRIX

KEY MARKET PLAYERS

MARKET SCOPE

WHAT IS IN IT FOR YOU: GLP-1 Agonists Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

RECENT DEVELOPMENTS

Table of Contents

Methodology

Secondary Research

Primary Research

Market Size Estimation

Bottom-up Approach and Top-down Approach

Data Triangulation

Market Definition

Stakeholders

Report Objectives

TABLE OF CONTENTS

METHODOLOGY

Personalize This Research

Let Us Help You

Growth opportunities and latent adjacency in GLP-1 Agonists Market